Zelira Therapeutics (AU:ZLD)
ASX:ZLD
Want to see AU:ZLD full AI Analyst Report?
ZLD Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$1.15
Previous CloseN/A
Volume190.00
Average Volume (3M)1.92K
Market Cap
AU$5.95M
Enterprise ValueAU$8.08M
Total Cash (Recent Filing)AU$5.66K
Total Debt (Recent Filing)AU$2.14M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,897,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Therapeutic FocusA concentrated strategy on cannabinoid-based medicines provides a clear, enduring product focus. Specialization supports accumulation of domain expertise, targeted regulatory and clinical experience, and tailored commercial approaches that can produce durable competitive advantages within this niche over multiple years.
End-to-End CapabilitiesOwning R&D, clinical evaluation, and regulated commercialisation creates structural control over the product lifecycle. This reduces reliance on external partners to bring products to market, helps capture more downstream value, and supports longer-term commercial execution if clinical programs succeed.
Improving Free Cash Flow TrendA reported slight improvement in free cash flow growth, even from negative levels, signals early operational stabilization. If sustained, improving FCF can lengthen runway, reduce financing dependence and allow focused investment in core programs over the medium term.
Bears Say
Severe Revenue DeclineA near-total collapse in reported revenue is a durable warning sign: it undermines scale economics, limits the ability to fund R&D and commercialisation internally, and indicates core commercial traction has failed. Recovering meaningful topline will take material time and investment.
Negative Equity / Balance Sheet RiskNegative shareholders' equity reflects pronounced balance-sheet instability and restricts financial flexibility. It signals prior losses have exhausted capital buffers, increasing the likelihood that the company will need external financing or restructuring to support operations and long-term programs.
Negative Cash Flow & MarginsSustained negative margins and cash outflows indicate the business is not self-financing. Persistent cash burn pressures strategic options, can dilute shareholders if equity financing is needed, and constrains investment in clinical and commercial programs essential for long-term growth.
Zelira Therapeutics News
ZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.31 and its highest was AU$1.15 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is AU$5.95M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 130 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics (ZLD) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid-based therapeutics. Operating primarily in the healthcare sector, Zelira aims to address various health conditions, including chronic pain, sleep disorders, and other serious ailments. The company leverages its proprietary formulations and clinical research to create products that are designed to improve patient outcomes and quality of life.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―